Back to Stocks

STTK

Shattuck Labs, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Shattuck Labs is entering a pivotal execution phase as its lead candidate, SL-325, prepares for a transition into Phase 2 clinical trials for Crohn's Disease in the third quarter of 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the reported cash balance, Shattuck Labs faces a precarious financial trajectory characterized by a relentless financing treadmill and significant dilution.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every STTK filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a crossroads between scientific promise and fiscal fragility. While the balance sheet has been fortified to $90.4 million, the cost of this liquidity has been significant shareholder dilution. The core investment thesis now rests on whether the mechanistic advantages of SL-325—specifically its potential to avoid the immunogenicity issues of TL1A blockers—can be proven in the upcoming Phase 2 trials. Investors must weigh the imminent clinical catalysts against the structural risks of a pre-revenue biotech. The transition to Phase 2 in Q3 2026 will be the definitive test of the DR3 platform. If the data proves superior, the current dilution may be viewed as a necessary cost of growth; however, any delay or failure in the clinical pipeline would leave the company vulnerable to a severe capital shortfall given its current burn rate.

Selected Quarter

Core Takeaway

Shattuck has secured the funding to reach its next major clinical milestone, but at the cost of substantial equity dilution.

Investor Lens

The trade-off is between the high-reward potential of a first-in-class DR3 antibody and the high-risk of equity dilution and binary clinical failure.

Watch Next

Phase 1 clinical trial completion and data readout expected in Q2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.20Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Increased cash position to $90.4M through ATM sales and warrant exercises.

capital raise
70%
bearishMay 7

Quarterly net loss of $14.8M reflecting continued high R&D burn.

earnings miss
40%
bearishMay 7

Over 47 million warrants outstanding create significant potential share dilution.

dilution risk
90%
bullishMay 7

Increased cash position to $90.4M through ATM sales and warrant exercises.

capital raise
70%
bearishMay 7

Quarterly net loss of $14.8M reflecting continued high R&D burn.

earnings miss
40%
bearishMay 7

Over 47 million warrants outstanding create significant potential share dilution.

dilution risk
90%
bullishMay 7

Increased cash position to $90.4M through ATM sales and warrant exercises.

capital raise
70%
bearishMay 7

Quarterly net loss of $14.8M reflecting continued high R&D burn.

earnings miss
40%
bearishMay 7

Over 47 million warrants outstanding create significant potential share dilution.

dilution risk
90%
bullishMay 7

Increased cash position to $90.4M through ATM sales and warrant exercises.

capital raise
70%
bearishMay 7

Quarterly net loss of $14.8M reflecting continued high R&D burn.

earnings miss
40%
bearishMay 7

Over 47 million warrants outstanding create significant potential share dilution.

dilution risk
90%
bullishMay 7

Increased cash position to $90.4M through ATM sales and warrant exercises.

capital raise
70%
bearishMay 7

Quarterly net loss of $14.8M reflecting continued high R&D burn.

earnings miss
40%
bearishMay 7

Over 47 million warrants outstanding create significant potential share dilution.

dilution risk
90%
bullishMay 7

Increased cash position to $90.4M through ATM sales and warrant exercises.

capital raise
70%
bearishMay 7

Quarterly net loss of $14.8M reflecting continued high R&D burn.

earnings miss
40%
bearishMay 7

Over 47 million warrants outstanding create significant potential share dilution.

dilution risk
90%
bullishMay 7

Increased cash position to $90.4M through ATM sales and warrant exercises.

capital raise
70%
bearishMay 7

Quarterly net loss of $14.8M reflecting continued high R&D burn.

earnings miss
40%
bearishMay 7

Over 47 million warrants outstanding create significant potential share dilution.

dilution risk
90%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a crossroads between scientific promise and fiscal fragility. While the balance sheet has been fortified to $90.4 million, the cost of this liquidity has been significant shareholder dilution. The core investment thesis now rests on whether the mechanistic advantages of SL-325—specifically its potential to avoid the immunogenicity issues of TL1A blockers—can be proven in the upcoming Phase 2 trials. Investors must weigh the imminent clinical catalysts against the structural risks of a pre-revenue biotech. The transition to Phase 2 in Q3 2026 will be the definitive test of the DR3 platform. If the data proves superior, the current dilution may be viewed as a necessary cost of growth; however, any delay or failure in the clinical pipeline would leave the company vulnerable to a severe capital shortfall given its current burn rate.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.